Propanc Biopharma (PPCB) Stock News
$PPCB · NASDAQ · HEALTHCARE · 2 stories in 30 days$0.33
1D −2.78%1W −26.67%1M −55.40%
BORSA has published 2 stories on Propanc Biopharma (PPCB) in the past 30 days. BORSA’s news read on PPCB is bullish at 65/100, based on 1 company event over the past 7 days. PPCB last closed at $0.37 on Oct 14, down 26.67% over five sessions and down 55.40% over the past month. Propanc Biopharma’s next earnings report is scheduled for Friday, Nov 13.
The wire on $PPCB
newest first · updated · direct subject stories onlyPropanc Biopharma's PRP reprograms chemotherapy-resistant pancreatic cancer cells in preclinical study
Propanc Biopharma (PPCB) released preclinical data showing its lead candidate PRP can remodel chemotherapy-resistant pancreatic cancer cells, restoring sensitivity to subsequent chemotherapy. The study found PRP reduced proliferation by over 50%, suppressed invasion and migration, and reversed markers of aggressive tumor behavior. The company plans a Phase 1b first-in-human study in Q1 2027.
bullish 65 · impact 40